Amgen Unveils Biosimilar Plans Amid Questions of Brand-Drug Bullying

Generic Line
Amid accusations of follow-on biologic blocking, Amgen has unveiled plans to develop half a dozen biosimilar products by 2017 as part of its long-term global growth strategy.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00